Evidence map›Paper›PMID 27323899›Full record

ArticleScientific reports2016

Water-soluble benzylidene cyclopentanone based photosensitizers for in vitro and in vivo antimicrobial photodynamic therapy.

Yanyan Fang, Tianlong Liu, Qianli Zou, Yuxia Zhao, Feipeng Wu

Abstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Photodynamic disinfection and its role in controlling infectious diseases.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2021
    Review
  5. Article
  6. Article
  7. Recent Patents on Light-Based Anti-Infective Approaches.Recent patents on anti-infective drug discovery · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanyan FangTechnical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Tianlong LiuTechnical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Qianli ZouTechnical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Yuxia ZhaoTechnical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Feipeng WuTechnical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial photodynamic therapy (aPDT) has been proposed to cope with the increasing antibiotic resistance among pathogens. As versatile pharmacophores, benzylidene cyclopentanone based photosensitizers (PSs) have been used in various bioactive materials. However, their reports as aPDT agents are very limited, and relationships between their chemical structures and antibacterial abilities have not been systematically discussed. Here, nine water-soluble benzylidene cyclopentanone PSs modified by polyethylene glycol (PEG), carboxylate anionic or pyridyl cationic agents are studied for aPDT. It is found that the binding/uptake abilities and aPDT effects of these PSs toward bacterial cells vary significantly when adjusting the number and position of their terminal charged groups. Though the comparable (also best) binding/uptake amounts are achieved by both cationic PS P3 and anionic PS Y1, only Y1 exhibits much more excellent aPDT activities than other PSs. Antibacterial mechanisms reveal that, relative to the favorable cell wall-binding of cationic PS P3, the anionic PS Y1 can accumulate more in the spheroplast/protoplast of methicillin-resistant Staphylococcus aureus (MRSA), which ensures its high efficient aPDT abilities both in vitro and in vivo. This study suggests the great clinical application potential of Y1 in inactivation of MRSA.

Indexed as

AnimalsAnti-Bacterial AgentsBiofilmsCyclopentanesDrug Resistance, MicrobialEscherichia coliLipidsMaleMethicillin-Resistant Staphylococcus aureusMiceMice, Inbred ICRMicrobial Sensitivity TestsPhotochemotherapyPhotosensitizing AgentsPolyethylene GlycolsSinglet OxygenAnti-Bacterial AgentsCyclopentanescyclopentanoneLipidsPhotosensitizing AgentsPolyethylene GlycolsSinglet OxygenWater

Identifiers

PMID27323899
PMCPMC4914934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.